Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd. is a global commercial-stage biotechnology company founded in 2007. They are committed to developing and commercializing innovative vaccines to improve health globally. Clover leverages the Trimer-Tag technology platform and its in-house manufacturing and commercial capabilities. Their product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment.